The block deal constituted 1.49% of the company's equity.
Meanwhile, the BSE Sensex was down 109.16 points, or 0.75%, 14,536.31.
On BSE, 5.45 lakh shares were traded in the counter. The stock had an average daily volume of 64,845 shares in the past one quarter.
The stock hit a high of Rs 491 and a low of Rs 457.10 so far during the day. The stock hit a 52-week high of Rs 528 on 25 June 2009 and a 52-week low of Rs 101.60 on 6 November 2008.
The mid-cap stock had outperformed the market over the past one month till 1 July 2009, gaining 22.47% as compared to the Sensex's 1.32% fall. It had also outperformed the market in the past one quarter, surging 161.29% as compared to the Sensex's return of 47.90%.
The company's current equity is Rs 26.88 crore. Face value per share is Rs 5.
The current price of Rs 470 discounts the company's Q4 March 2009 annualized EPS of Rs 67.25, by a PE multiple of 6.99.
Aurobindo Pharma had on 23 June 2009 secured nod from South Africa's Medicines Control Council (MCC) to manufacture and market five more products in that country. The approved drugs are Auro-Abacavir tablet in 300 miligram (mg), Auro-Abacavir Oral Solution in 20mg /mili litre (ml), Auroprozil tablet in 250 & 500 mg, Injection Auro-Cefotaxime in 250 mg, 500 mg, 1000 mg and 2000 mg and Auro-Cefalexin tablet in 250 mg & 750 mg.
Aurobindo Pharma Australia Pty, a wholly owned subsidiary of Aurobindo Pharma, had on 15 June 2009 received approval from Therapeutic Goods Administration (TGA), government of Australia for the registration Amlodipine Besylate tablets in multiple strengths. The drug is indicated for treating hypertension.
Aurobindo Pharma had on 21 May 2009 further expanded its partnership with Pfizer Inc by executing licensing and supply agreements with the latter for solid dosage and sterile products for a number of emerging markets.
Under the terms of the pact, Pfizer acquired rights to 55 solid oral dose and 5 sterile injectable products for several countries throughout Asia, Latin America and West Asia. These products fall under a broad range of some important therapeutic segments like anti-infectives, cardivascular (CVS) and central nervous system (CNS) disorders.
Earlier in March 2009, Pfizer had extended an agreement with Aurobindo whereby it acquired rights to sell 39 generic drugs in the US, 20 in Europe and 11 in France. This agreement extends a deal under which Pfizer bought licenses from Aurobindo in July last year to sell five generic drugs in the US.
Aurobindo Pharma's net profit rose 18.80% to Rs 90.38 crore on 22.80% increase in net sales to Rs 786.55 crore in Q4 March 2009 over Q4 March 2008.
Aurobindo, which started off as a supplier of drug raw materials to semi- regulated markets, has moved up the value chain and currently sells finished generic drugs in regulated markets.
Aurobindo Pharma had on 12 June 2009 announced that K Rajeswari, a promoter of the company, revoked the entire shares, which she had pledged earlier.
On the same day, the company had announced that K Nithyananda Reddy, another promoter, revoked two lakh shares representing 0.37% of the equity capital of the company out of 9.25 lakh shares representing 1.72% of the equity capital of the company, which he had pledged earlier. K Nithyananda Reddy held 4.19% stake in the company as on 31 March 2009.
The company had on 11 June 2009 announced that PV Ramprasad Reddy, Chairman and a promoter of Aurobindo Pharma had revoked more than 26.84 lakh shares representing 4.99% of the company's equity capital out of which he had pledged more than 1.51 crore shares representing 28.09% of the equity capital of the firm. Ramprasad held 31.56% stake in the company as on 31 March 2009.
On the same day, the company had announced that K Kirthi Reddy, a promoter had revoked 3.85 lakh shares or 0.72% of the equity capital of the company out of 8.90 lakh shares representing 1.66% of the company capital of the company he had pledged earlier. K Kirthi Reddy held 4% stake in the company as on 31 March 2009.
The total promoter shareholding in the company is 59.85% on 31 March 2009.